© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
October 22, 2013
Results from a small study show that vemurafenib is an effective and well-tolerated treatment option for patients with BRAF V600E-positive papillary thyroid cancer.
Case study shows ultrasound-guided percutaneous ethanol ablation is a well-tolerated and effective option for patients with thyroid cancer who elect not to undergo thyroidectomy.
Radiofrequency ablation and percutaneous laser ablation are both effective and safe for the management of benign thyroid nodules, with no significant differences in nodule volume reduction between the two techniques.
Researchers report that overweight and obese patients undergoing minimally invasive video-assisted thyroidectomy (MIVAT) are not at increased risk for surgical complications.